Scott Smith
@Acuta Capital Partners, Llc
Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.
Assets under management
The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
TERNTerns Pharmaceuticals Inc
| 3.29% | $4.062M 487,000 shares@ $8.34 avg price | Increased 31.88% |
KURAKura Oncology Inc. Common Stock
| 3.12% | $3.849M 197,000 shares@ $19.54 avg price | Increased 20.86% |
AADIAadi Biosciences Inc
| 3.09% | $3.81M 1.849M shares@ $2.06 avg price | |
RCKTRocket Pharmaceuticals Inc
| 2.85% | $3.509M 190,000 shares@ $18.47 avg price | Decreased -24.11% |
PRAXPraxis Precision Medicines I
| 2.68% | $3.309M 57,500 shares@ $57.54 avg price | Decreased -65.03% |
ARGXArgenx Se
| 2.6% | $3.198M 5,900 shares@ $542.08 avg price | Increased 47.5% |
ASNDAscendis Pharma A S
| 2.54% | $3.136M 21,000 shares@ $149.31 avg price | New Position |
CMPSCompass Pathways Plc
| 1.98% | $2.435M 386,500 shares@ $6.3 avg price | New Position |
MRSNMersana Therapeutics Inc
| 1.84% | $2.268M 1.2M shares@ $1.89 avg price | Decreased -27.84% |
HLXBHelix Acquisition Corp Ii
| 1.54% | $1.891M 180,945 shares@ $10.45 avg price | Increased 1.75% |